S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Invitae Stock Forecast, Price & News

+0.29 (+2.53%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
6.30 million shs
Average Volume
5.34 million shs
Market Capitalization
$2.66 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

Invitae logo

About Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.


Invitae (NYSE:NVTA) Stock Price Down 5.5%
January 12, 2022 |  americanbankingnews.com
Invitae (NYSE:NVTA) Hits New 12-Month Low at $11.70
January 10, 2022 |  americanbankingnews.com
Invitae (NYSE:NVTA) Shares Up 6.9%
January 7, 2022 |  americanbankingnews.com
Should You Invest in Invitae Right Now?
January 2, 2022 |  finance.yahoo.com
Invitae (NYSE:NVTA) Shares Down 6.3%
December 27, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Year Founded

Sales & Book Value

Annual Sales
$279.60 million
Book Value
$10.63 per share


Net Income
$-602.17 million
Net Margins
Pretax Margin




Free Float
Market Cap
$2.66 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.17 out of 5 stars

Medical Sector

425th out of 1,405 stocks

Medical Laboratories Industry

9th out of 30 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae
or view top-rated stocks.

How has Invitae's stock been impacted by COVID-19 (Coronavirus)?

Invitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVTA stock has decreased by 25.9% and is now trading at $11.74.
View which stocks have been most impacted by COVID-19

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Invitae

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) posted its quarterly earnings data on Sunday, November, 7th. The medical research company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.22. The medical research company had revenue of $114.40 million for the quarter, compared to analyst estimates of $126.56 million. Invitae had a negative trailing twelve-month return on equity of 23.02% and a negative net margin of 155.87%. The company's quarterly revenue was up 66.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.62) earnings per share.
View Invitae's earnings history

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $450 million-$475 million, compared to the consensus revenue estimate of $484.54 million.

What price target have analysts set for NVTA?

8 brokers have issued 12 month price targets for Invitae's shares. Their forecasts range from $25.00 to $58.00. On average, they anticipate Invitae's share price to reach $40.63 in the next twelve months. This suggests a possible upside of 246.0% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Sean Emerson George, Chairman, President & Chief Executive Officer
  • Kenneth D. Knight, Chief Operating Officer
  • Roxi Wen, Chief Financial Officer
  • Robert Nussbaum, Chief Medical Officer (LinkedIn Profile)
  • Layton Wedgeworth, Chief Technology Officer

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Green Alpha Advisors LLC (0.02%), Wedbush Securities Inc. (0.02%) and Vigilare Wealth Management (0.02%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae

Which institutional investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Green Alpha Advisors LLC, and Wedbush Securities Inc.. Company insiders that have sold Invitae company stock in the last year include Artur Bergman, Geoffrey Crouse, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae
or view top insider-selling stocks.

Which institutional investors are buying Invitae stock?

NVTA stock was purchased by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for Invitae
or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $11.74.

How much money does Invitae make?

Invitae has a market capitalization of $2.66 billion and generates $279.60 million in revenue each year. The medical research company earns $-602.17 million in net income (profit) each year or ($3.45) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 2,100 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

Where are Invitae's headquarters?

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at (415) 374-7782 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.